PainReform (PRFX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PainReform Ltd. reported promising initial results from its Phase 3 trial of PRF-110, highlighting its potential to significantly reduce post-surgical pain within the first 48 hours after bunionectomy surgery. However, challenges remain as data for the following 24-hour period is currently unclear. The company is working to address these data issues to provide a comprehensive analysis of PRF-110’s efficacy.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.